Teflaro
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Teflaro (ceftaroline fosamil; Actavis/AstraZeneca/Dainippon Sumitomo Pharma) is a fifth-generation cephalosporin. The highly water-soluble prodrug ceftaroline fosamil is quickly converted in the blood to the active agent ceftaroline upon administration. The drug targets penicillin-binding proteins on susceptible bacterial strains. It inhibits bacterial cell wall synthesis, reduces the integrity of the bacterial cell wall, and ultimately causes cell death. Teflaro is active against a wide range of Gram-positive bacterial strains including Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus agalactiae. It also has activity against some Gram-negative strains including E. coli, Klebsiella pneumonia, and Klebsiella oxytoca. Furthermore, the drug has also demonstrated bactericidal activity against some multidrug-resistant bacterial strains including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate Staphylococcus aureus, as well as Zyvox-resistant and Cubicin-non-susceptible strains, but it is not effective against extended-spectrum beta-lactamase-producing Gram-negative bacteria. Teflaro’s activity against MRSA stems from its ability to bind to a penicillin-binding protein specific to this bacterial strain called the PBP2a.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Teflaro : Community-acquired pneumonia
16 Teflaro : Skin and skin structure infections
LIST OF FIGURES
8 Figure 1: Phase III data for Teflaro in the treatment of community-acquired pneumonia in
Asian patients
9 Figure 2: Teflaro for community-acquired pneumonia – SWOT analysis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Teflaro in communityacquired
pneumonia
11 Figure 4: Datamonitor Healthcare’s drug assessment summary of Teflaro in communityacquired
pneumonia
20 Figure 5: Teflaro – SWOT analysis in cSSSI
22 Figure 6: Datamonitor Healthcare’s drug assessment summary of Teflaro in cSSSI
22 Figure 7: Datamonitor Healthcare’s drug assessment summary for Teflaro in cSSSI
LIST OF TABLES
4 Table 1: Teflaro drug profile
6 Table 2: Overview of pivotal trial data for Teflaro in community-acquired pneumonia
16 Table 3: Teflaro’s drug profile in cSSSI
18 Table 4: Overview of pivotal trial data for Teflaro in ABSSSI
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Aducanumab 
Sign up to the